Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective
暂无分享,去创建一个
A. Schneeweiss | H. Tesch | N. Harbeck | M. Untch | G. von Minckwitz | J. Huober | C. Jackisch | C. Thomssen | A. Scharl | T. Decker | H. Lück | R. Wuerstlein | S. Hegewisch‐Becker | A. Welt | N. Marschner
[1] N. Harbeck,et al. Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations , 2013, Drugs.
[2] D. Amadori,et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. , 2013, The oncologist.
[3] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[4] M. Piccart,et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.
[5] Sung-Bae Kim,et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.